Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
36.93
-0.29 (-0.78%)
At close: Jun 18, 2025, 4:00 PM
37.36
+0.43 (1.16%)
After-hours: Jun 18, 2025, 6:56 PM EDT
Zai Lab Revenue
Zai Lab had revenue of $106.49M in the quarter ending March 31, 2025, with 22.19% growth. This brings the company's revenue in the last twelve months to $418.33M, up 43.72% year-over-year. In the year 2024, Zai Lab had annual revenue of $398.99M with 49.59% growth.
Revenue (ttm)
$418.33M
Revenue Growth
+43.72%
P/S Ratio
8.97
Revenue / Employee
$223,823
Employees
1,869
Market Cap
4.01B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 398.99M | 132.27M | 49.59% |
Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ZLAB News
- 6 days ago - Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025 - Business Wire
- 17 days ago - Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting - Business Wire
- 18 days ago - Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Business Wire
- 20 days ago - Zai Lab Announces Participation in Investor Conferences in June 2025 - Business Wire
- 22 days ago - Zai Lab Limited Is Well Positioned For Long-Term Growth - Seeking Alpha
- 4 weeks ago - Zai Lab Limited: Banking On Chinese Pharma Growth - Seeking Alpha
- 4 weeks ago - Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer - Business Wire
- 5 weeks ago - Zai Lab Limited (ZLAB) Q1 2025 Earnings Call Transcript - Seeking Alpha